This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Baniahmad, A. Articles by Renkawitz, R. Search for Related Content PubMed PubMed Citation Articles by Baniahmad, A. Articles by Renkawitz, R. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB TRANS-RETINOIC ACID

Cell-Specific Inhibition of Retinoic Acid Receptor- Silencing by the AF2/c Activation Domain Can Be Overcome by the Corepressor SMRT, But Not by N-CoR

Genetisches Institut der Justus-Liebig Universität D-35392 Giessen, Germany

The human retinoic acid receptor (hRAR) exhibits cell-specific transcriptional activity. Previously, it was shown that in the absence of hormone the wild-type receptor is a transcriptional silencer in L cells, whereas it lacks silencing function and is a weak activator in CV1 cells. Addition of hormone leads to a further increase in transactivation in CV1 cells. Thus, the retinoic acid response mediated by RAR is weak in these cells. It was shown that the CV1-specific effect is due to the receptor C terminus. We show, that the failure of silencing by RAR is not due to a general lack of corepressors in CV1 cells, since the silencing domain of RAR is functionally active and exhibits active repression in these cells. Furthermore, we show that the conserved AF2/c activation function of RAR is responsible for the cell-specific inhibition of silencing. Thereby, the CV1 cell specificity was abolished by replacing AF2/c of RAR with the corresponding sequence of the thyroid hormone receptor. Thus, we find a new role of the C-terminal conserved activation function AF2/c in that, specifically, the RAR AF2/c-sequence is able to prevent silencing of RAR in a cell-specific manner. In addition, we show that the inhibitory effect of AF2/c in CV1 cells can be overcome by expression of the corepressor SMRT (silencing mediator of retinoic acid and thyroid hormone receptor), but not by that of N-CoR (nuclear receptor corepressor). The expression of these two corepressors, however, had no measurable effect on RAR-mediated silencing in L cells. Thus, the expression of a corepressor can lead to a dramatic increase of hormonal response in a cell-specific manner.

This article has been cited by other articles:

				S. Cote, S. McNamara, D. Brambilla, A. Bianchini, G. Rizzo, S. V. del Rincon, F. Grignani, C. Nervi, and W. H. Miller Jr Expression of SMRT{beta} promotes ligand-induced activation of mutated and wild-type retinoid receptors Blood, December 15, 2004; 104(13): 4226 - 4235. [Abstract] [Full Text] [PDF]

				B. Farboud and M. L. Privalsky Retinoic Acid Receptor-{alpha} Is Stabilized in a Repressive State by Its C-Terminal, Isotype-Specific F Domain Mol. Endocrinol., December 1, 2004; 18(12): 2839 - 2853. [Abstract] [Full Text] [PDF]

				Q. Wang, J. A. Blackford Jr., L.-N. Song, Y. Huang, S. Cho, and S. S. Simons Jr. Equilibrium Interactions of Corepressors and Coactivators with Agonist and Antagonist Complexes of Glucocorticoid Receptors Mol. Endocrinol., June 1, 2004; 18(6): 1376 - 1395. [Abstract] [Full Text] [PDF]

				H. Hauksdottir, B. Farboud, and M. L. Privalsky Retinoic Acid Receptors {beta} and {gamma} Do Not Repress, But Instead Activate Target Gene Transcription in Both the Absence and Presence of Hormone Ligand Mol. Endocrinol., March 1, 2003; 17(3): 373 - 385. [Abstract] [Full Text] [PDF]

				H. Dotzlaw, U. Moehren, S. Mink, A. C. B. Cato, J. A. Iniguez Lluhi, and A. Baniahmad The Amino Terminus of the Human AR Is Target for Corepressor Action and Antihormone Agonism Mol. Endocrinol., April 1, 2002; 16(4): 661 - 673. [Abstract] [Full Text] [PDF]

				G. Giannoukos, D. Szapary, C. L. Smith, J. E. W. Meeker, and S. S. Simons Jr. New Antiprogestins with Partial Agonist Activity: Potential Selective Progesterone Receptor Modulators (SPRMs) and Probes for Receptor- and Coregulator-Induced Changes in Progesterone Receptor Induction Properties Mol. Endocrinol., February 1, 2001; 15(2): 255 - 270. [Abstract] [Full Text]

				L. J. BURKE and A. BANIAHMAD Co-repressors 2000 FASEB J, October 1, 2000; 14(13): 1876 - 1888. [Abstract] [Full Text]

				D. Szapary, Y. Huang, and S. S. Simons Jr. Opposing Effects of Corepressor and Coactivators in Determining the Dose-Response Curve of Agonists, and Residual Agonist Activity of Antagonists, for Glucocorticoid Receptor-Regulated Gene Expression Mol. Endocrinol., December 1, 1999; 13(12): 2108 - 2121. [Abstract] [Full Text]

				N. J. McKenna, R. B. Lanz, and B. W. O’Malley Nuclear Receptor Coregulators: Cellular and Molecular Biology Endocr. Rev., June 1, 1999; 20(3): 321 - 344. [Abstract] [Full Text]

				U. Dressel, D. Thormeyer, B. Altincicek, A. Paululat, M. Eggert, S. Schneider, S. P. Tenbaum, R. Renkawitz, and A. Baniahmad Alien, a Highly Conserved Protein with Characteristics of a Corepressor for Members of the Nuclear Hormone Receptor Superfamily Mol. Cell. Biol., May 1, 1999; 19(5): 3383 - 3394. [Abstract] [Full Text] [PDF]